CoChat
Sign Up
Cited by 97

The DOI matches its Crossref record.

Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer

Chandran, Suriyakala Perumal, Natarajan, Satheesh Babu, Chandraseharan, Sowmiya, Mohd Shahimi, Masliza Suhaini Binti·2017·Journal of Cancer Research and Practice
DOI 10.1016/j.jcrpr.2017.02.002
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcrpr.2017.02.002

Cites

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 42

  1. Subudhi, 2015, Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil, Materials, 8, 832, 10.3390/ma8030832 · DOI
  2. Wasserberg, 2007, Palliation of colorectal cancer, Surgi Oncol, 16, 299, 10.1016/j.suronc.2007.08.008 · DOI
  3. Haggar, 2009, Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors, Clin Colon Rectal Surg, 22, 191, 10.1055/s-0029-1242458 · DOI
  4. Cirstoiu-Hapca, 2009, Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immuno nanoparticles and in vitro functional studies on target cells, Eur J Pharm Sci, 38, 230, 10.1016/j.ejps.2009.07.006 · DOI
  5. Shan, 2012, Traditional Chinese medicinal syndromes and treatment in colorectal cancer, J Cancer Ther, 3, 888
  6. Grem, 2000, 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development, Invest New Drugs, 18, 299, 10.1023/A:1006416410198 · DOI
  7. Maria, 2015, Efficacy of 5-FU or oxaliplatin monotherapy over combination therapy in colorectal cancer, J Cancer Ther, 6, 345
  8. Lin, 2002, A study of purified montmorillionitrite intercalated with 5-fluorouracil as drug carrier, Biomaterials, 23, 1981, 10.1016/S0142-9612(01)00325-8 · DOI
  9. Stephen, 2002, New treatments for advanced and metastatic colorectal cancer–clinical applications, Aust Prescr, 25, 111, 10.18773/austprescr.2002.111 · DOI
  10. Giacchetti, 2000, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil leucovorin as first-line treatment of metastatic colorectal cancer, J Clin Oncol, 18, 136, 10.1200/JCO.2000.18.1.136 · DOI
  11. Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 · DOI · Paper page
  12. Arias, 2008, Poly(alkyl cyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: a comparative study, Colloids Surf B Biointerfaces, 62, 64, 10.1016/j.colsurfb.2007.09.018 · DOI
  13. Yoshizawa, 2011, PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy, Int J Pharm, 412, 132, 10.1016/j.ijpharm.2011.04.008 · DOI
  14. Cho, 2010, Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging, Cancer Lett, 299, 63, 10.1016/j.canlet.2010.08.004 · DOI
  15. Patel, 2014, Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique, AAPS PharmSciTech, 15, 1498, 10.1208/s12249-014-0168-x · DOI
  16. Jenning, 2002, Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization, J Microencapsul, 19, 1, 10.1080/713817583 · DOI
  17. Lee, 2003, Microencapsulation of lipid nanoparticles containing lipophilic drug, J Microencapsul, 20, 489, 10.1080/0265204031000093032 · DOI
  18. Lohan, 2013, Formulation and evaluation of solid lipid nanoparticles of quetiapine fumarate and quetiapine hemifumarate for brain delivery in rat model, Pharm Nanotechnol, 1, 239, 10.2174/22117385113019990005 · DOI
  19. Yassin, 2010, Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer, Int J. Med Sci, 7, 398, 10.7150/ijms.7.398 · DOI
  20. Chang, 2006, Preparation and preliminary characterization of concentric multi-walled chitosan microspheres, J Biomed Mater Res A, 81, 554
  21. Jun, 2011, Recent advances of chitosan nanoparticles as drug carriers, Int J Nanomedicine, 6, 765
  22. Cao, 2005, Progress in antitumor studies of chitosan, Chin J Biochem Pharm, 26
  23. Shashank, 2015, Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer, Saudi Pharm J, 23, 308, 10.1016/j.jsps.2014.11.010 · DOI
  24. Seda, 2012, 5-Fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: evaluation of controlled release kinetics, J Nanomater, 2012, 1
  25. Fabienne, 2012, PLGA-based nanoparticles: an overview of biomedical applications, J Control Release, 161, 505, 10.1016/j.jconrel.2012.01.043 · DOI
  26. Sutar, 2013, Preparation and characterisation of 5-Fluorouracil loaded PLGA nanoparticles for colorectal cancer therapy, Unique J Pharm Boil Sci, 01, 52
  27. Park, 2005, Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folatemediated targeting of anticancer drugs, Biomaterials, 26, 1053, 10.1016/j.biomaterials.2004.04.008 · DOI
  28. Jayakumar, 2010, Biomedical applications of chitin and chitosan based nanomaterials – a short review, Carbohyd Polym, 82, 227, 10.1016/j.carbpol.2010.04.074 · DOI
  29. Li, 2011, Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells, Carbohyd Res, 346, 801, 10.1016/j.carres.2011.01.027 · DOI
  30. Sen, 2005, Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold, Bioconjug Chem, 16, 1572, 10.1021/bc050147l · DOI
  31. Elnakat, 2004, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv Drug Deliv Rev, 56, 1067, 10.1016/j.addr.2004.01.001 · DOI
  32. Lu, 2002, Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors, Cancer Immunol Immunother, 51, 153, 10.1007/s00262-002-0266-6 · DOI
  33. Zhang, 2007, 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice, J Control Release, 119, 153, 10.1016/j.jconrel.2007.02.013 · DOI
  34. Yichao, 2015, Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles, Drug Deliv, 22, 191, 10.3109/10717544.2013.875603 · DOI
  35. Moore, 1998, Soluble and insoluble fiber influences on cancer development, Crit Rev Oncol Hematol, 27, 229, 10.1016/S1040-8428(98)00006-7 · DOI
  36. Ohulchanskyy, 2007, Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer, Nano Lett, 7, 2835, 10.1021/nl0714637 · DOI
  37. Karbownik, 2013, Hyaluronan: towards novel anti-cancer therapeutics, Pharmacol Rep, 65, 1056, 10.1016/S1734-1140(13)71465-8 · DOI
  38. Kai, 2015, Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation, Int J Nanomedicine, 10, 6445
  39. Lijue, 2015, Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles, Nanoscale, 7, 14080, 10.1039/C5NR03527A · DOI
  40. Zhang, 2006, Synthesis and biological evaluation of new 4beta-5Fu-substituted 4'-demethylepipodophyllotoxin derivatives, Molecules, 11, 849, 10.3390/11110849 · DOI
  41. Tian, 2007, Synthesis and bioevaluation of 5-fluorouracil derivatives, Molecules, 12, 2450, 10.3390/12112450 · DOI
  42. Haijun, 2016, Onivyde for the therapy of multiple solid tumors, Onco Targets Ther, 9, 3001

Cited by

Sorted by citations

Metadata

Authors
Chandran, S. P., Natarajan, S. B., Chandraseharan, S., & Mohd Shahimi, M. S. B.
Venue
Journal of Cancer Research and Practice
Publisher
Medknow
Published
2017-06
Volume
4
Issue
2
Pages
45-48
ISSN
2311-3006
DOI
10.1016/j.jcrpr.2017.02.002
Cited by
97
References
0
Language
en
Licence
Funders
Fundamental Research Grant Scheme (FRGS/1/2014/SKK02/LINCOLN/03/1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review